Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Insider Sells $107,085.07 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Dianne C. Whitfield sold 2,137 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $50.11, for a total transaction of $107,085.07. Following the completion of the transaction, the insider now owns 46,355 shares of the company’s stock, valued at $2,322,849.05. This trade represents a 4.41 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Tarsus Pharmaceuticals Stock Up 0.1 %

Tarsus Pharmaceuticals stock opened at $49.97 on Friday. Tarsus Pharmaceuticals, Inc. has a 1-year low of $20.08 and a 1-year high of $57.28. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The stock has a market cap of $1.92 billion, a PE ratio of -13.12 and a beta of 1.05. The stock’s fifty day moving average is $48.48 and its two-hundred day moving average is $45.35.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The company had revenue of $66.41 million for the quarter, compared to analysts’ expectations of $58.80 million. On average, sell-side analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Institutional Trading of Tarsus Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Crowley Wealth Management Inc. acquired a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter worth about $25,000. GF Fund Management CO. LTD. acquired a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter worth about $44,000. R Squared Ltd acquired a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter worth about $53,000. FMR LLC increased its position in shares of Tarsus Pharmaceuticals by 236.6% during the third quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after purchasing an additional 3,537 shares in the last quarter. Finally, Quarry LP acquired a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter worth about $166,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on TARS shares. Guggenheim restated a “buy” rating and issued a $78.00 price objective (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. Barclays dropped their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Oppenheimer lifted their price objective on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. Jefferies Financial Group boosted their price target on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. Finally, HC Wainwright restated a “buy” rating and issued a $73.00 price objective on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Tarsus Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $63.67.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.